Taxane rechallenge during metastatic disease in HER-2 negative breast cancer patients: Clinical activity, tolerance and survival results.

Date publication

février 2023

Journal

Breast (Edinburgh, Scotland)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BERTAUT Aurélie , Dr COUDERT Bruno , Dr LADOIRE Sylvain , Dr DESMOULINS Isabelle , Dr HENNEQUIN Audrey , Dr MAYEUR Didier , Dr REDA Manon

Tous les auteurs :
Réda M, Fouquier A, Desmoulins I, Mayeur D, Kaderbhai C, Ilie S, Hennequin A, Coudert B, Bertaut A, Ladoire S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36773403

Résumé

Taxanes are major drugs for metastatic breast cancer (MBC) treatment, and are generally well tolerated, making them attractive for therapeutic reintroduction (rechallenge) during metastatic course. In view of the paucity of current literature, we questioned the usefulness of taxane rechallenge in a population of patients previously treated with taxanes in a metastatic setting.

Mots clés

Breast cancer, Chemotherapy, Docetaxel, Metastatic cancer, Paclitaxel, Rechallenge, Taxanes

Référence

Breast. 2023 02 4;68:149-156